Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neuroleptic malignant syndrome and the catatonic dilemma

Neuroleptic malignant syndrome and the catatonic dilemma Psychopharmacology (2015) 232:661–662 DOI 10.1007/s00213-015-3864-7 LETTER TO THE EDITOR Stanley N. Caroff & Stephan C. Mann & E. Cabrina Campbell Received: 28 December 2014 /Accepted: 1 January 2015 /Published online: 16 January 2015 Springer-Verlag Berlin Heidelberg (outside the USA) 2015 To the editor; drug cessation provides a resolution of the catatonic dilemma In their scholarly analysis of published reports of neuroleptic and an “external validation” of the diagnosis of NMS, albeit malignant syndrome (NMS) and catatonia, Lang et al. (2014) post hoc. However, if symptoms of NMS do not resolve after found 12 variables with statistically significant discriminatory drug discontinuation, evidence has also been published sug- power in differentiating the 2 disorders. Given the seriousness gesting several drug treatments, including lorazepam, and of these disorders, the infrequency of their occurrence, and the ECT may improve recovery (Davis et al. 2000). general lack of research data and awareness among clinicians, Second, it is not surprising that Lang et al. found that symp- the analysis by Lang et al. to differentiate NMS from catatonia toms of parkinsonism (rigidity and tremor) are more common is an important endeavor. However, there are three points we in NMS than in cases of catatonia. In http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychopharmacology Springer Journals

Neuroleptic malignant syndrome and the catatonic dilemma

Psychopharmacology , Volume 232 (3) – Feb 1, 2015

Loading next page...
 
/lp/springer-journals/neuroleptic-malignant-syndrome-and-the-catatonic-dilemma-qAz2R5l8Bs

References (12)

Publisher
Springer Journals
Copyright
Copyright © 2015 by Springer-Verlag Berlin Heidelberg
Subject
Biomedicine; Neurosciences; Pharmacology/Toxicology; Psychiatry
ISSN
0033-3158
eISSN
1432-2072
DOI
10.1007/s00213-015-3864-7
pmid
25589146
Publisher site
See Article on Publisher Site

Abstract

Psychopharmacology (2015) 232:661–662 DOI 10.1007/s00213-015-3864-7 LETTER TO THE EDITOR Stanley N. Caroff & Stephan C. Mann & E. Cabrina Campbell Received: 28 December 2014 /Accepted: 1 January 2015 /Published online: 16 January 2015 Springer-Verlag Berlin Heidelberg (outside the USA) 2015 To the editor; drug cessation provides a resolution of the catatonic dilemma In their scholarly analysis of published reports of neuroleptic and an “external validation” of the diagnosis of NMS, albeit malignant syndrome (NMS) and catatonia, Lang et al. (2014) post hoc. However, if symptoms of NMS do not resolve after found 12 variables with statistically significant discriminatory drug discontinuation, evidence has also been published sug- power in differentiating the 2 disorders. Given the seriousness gesting several drug treatments, including lorazepam, and of these disorders, the infrequency of their occurrence, and the ECT may improve recovery (Davis et al. 2000). general lack of research data and awareness among clinicians, Second, it is not surprising that Lang et al. found that symp- the analysis by Lang et al. to differentiate NMS from catatonia toms of parkinsonism (rigidity and tremor) are more common is an important endeavor. However, there are three points we in NMS than in cases of catatonia. In

Journal

PsychopharmacologySpringer Journals

Published: Feb 1, 2015

There are no references for this article.